Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor OTC Switch Would Force Pfizer To Clear Big Research Hurdles

This article was originally published in The Tan Sheet

Executive Summary

Pfizer would face major hurdles in research on consumers’ safe self-selection for FDA to approve an OTC switch of the firm’s cholesterol treatment Lipitor.
Advertisement

Related Content

Nexium OTC Switch Would Face Crowded Field, Potential Questions
Nexium OTC Switch Would Face Crowded Field, Potential Questions
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
FDA Digs Deeper On “New Paradigm” To Expand Rx Switches
OTC Switch “Blueprint” Could Help Regulatory Navigation – Researchers
Pfizer Will Unload Nutrition Division, Keep Consumer Product Unit
Pfizer Consumer Chief Sees Chronic Conditions In OTC Future
CDER Director Sees Behind-The-Counter Switches As Best Bet
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins

Topics

Advertisement
UsernamePublicRestriction

Register

PS105226

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel